Higher efficacy of resveratrol against advanced breast cancer organoids: A comparison with that of clinically relevant drugs

Abstract The lack of reliable drugs is a therapeutic challenge of advanced breast cancers (ABCs). Resveratrol (Res) exerts inhibitory effects on breast cancer cell lines and animal models, while its efficacy against individual breast cancer cases remains unknown. This study aims to use ABC‐derived organoids (ABCOs) as the ex vivo therapeutic platform to clarify the effectiveness of resveratrol against different ABC subtypes. Immunohistochemical staining confirmed that the ABCOs maintained their original tumors' ER, PR, HER2, and Ki67 expression patterns. ABCO proliferation and viability tests showed >50% cell death rates in 79.2% (19/24) of Res‐treated, 28.6% (2/7) fulvestrant‐treated, 66.7% (4/6) paclitaxel‐treated, and 66.7% (6/9) gemcitabine‐treated ABCOs. pSTAT3 nuclear translocation was more frequent in Res‐sensitive (17/19; 89.47%) than that (1/5; 20%) of Res‐insensitive ABCOs, which were suppressed upon Res treatment. Statistical analysis revealed a close correlation of STAT3 activation with the efficacy of Res, but not related to tumor receptor expression patterns (ER, PR, HER2) and pathological classification. We demonstrate for the first time the higher efficacy and broader spectrum of Res against different subtypes of ABCOs in comparison with that of conventional antibreast cancer drugs, providing an alternative approach for better management of ABCs.